AU2016248886B2 - Pyridopyrimidinones and their use as NMDA receptor modulators - Google Patents

Pyridopyrimidinones and their use as NMDA receptor modulators Download PDF

Info

Publication number
AU2016248886B2
AU2016248886B2 AU2016248886A AU2016248886A AU2016248886B2 AU 2016248886 B2 AU2016248886 B2 AU 2016248886B2 AU 2016248886 A AU2016248886 A AU 2016248886A AU 2016248886 A AU2016248886 A AU 2016248886A AU 2016248886 B2 AU2016248886 B2 AU 2016248886B2
Authority
AU
Australia
Prior art keywords
methyl
pyrido
oxo
trifluoromethyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016248886A
Other languages
English (en)
Other versions
AU2016248886A1 (en
Inventor
Yu Jiang
Aijun Lu
Benjamin SELLERS
Elisia VILLEMURE
Matthew Volgraf
Guosheng Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2016248886A1 publication Critical patent/AU2016248886A1/en
Application granted granted Critical
Publication of AU2016248886B2 publication Critical patent/AU2016248886B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2016248886A 2015-04-15 2016-04-12 Pyridopyrimidinones and their use as NMDA receptor modulators Ceased AU2016248886B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/076617 2015-04-15
CN2015076617 2015-04-15
PCT/EP2016/057962 WO2016166078A1 (en) 2015-04-15 2016-04-12 Pyridopyrimidinones and their use as nmda receptor modulators

Publications (2)

Publication Number Publication Date
AU2016248886A1 AU2016248886A1 (en) 2017-10-12
AU2016248886B2 true AU2016248886B2 (en) 2020-09-10

Family

ID=55809078

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016248886A Ceased AU2016248886B2 (en) 2015-04-15 2016-04-12 Pyridopyrimidinones and their use as NMDA receptor modulators

Country Status (19)

Country Link
US (1) US10280165B2 (enExample)
EP (1) EP3283487B1 (enExample)
JP (2) JP6847851B2 (enExample)
KR (1) KR20170137137A (enExample)
CN (1) CN107531696B (enExample)
AU (1) AU2016248886B2 (enExample)
BR (1) BR112017021083A2 (enExample)
CA (1) CA2982217A1 (enExample)
CL (1) CL2017002498A1 (enExample)
CO (1) CO2017009989A2 (enExample)
CR (1) CR20170462A (enExample)
IL (1) IL254921B (enExample)
MX (1) MX373162B (enExample)
PE (1) PE20180316A1 (enExample)
PH (1) PH12017501876A1 (enExample)
RU (1) RU2717665C2 (enExample)
SG (1) SG11201708294YA (enExample)
UA (1) UA120647C2 (enExample)
WO (1) WO2016166078A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3055315T (pt) 2013-10-11 2018-10-25 Hoffmann La Roche Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda
PE20180316A1 (es) 2015-04-15 2018-02-09 Hoffmann La Roche Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda
ES2821010T3 (es) 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações
CN116322696A (zh) 2020-05-04 2023-06-23 安进公司 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014202493A1 (en) * 2013-06-19 2014-12-24 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
ES2339862T3 (es) * 2003-06-20 2010-05-26 Novartis Vaccines And Diagnostics, Inc. Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos.
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
CA2677493A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
PT3055315T (pt) * 2013-10-11 2018-10-25 Hoffmann La Roche Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda
PE20180316A1 (es) 2015-04-15 2018-02-09 Hoffmann La Roche Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014202493A1 (en) * 2013-06-19 2014-12-24 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KENNIS L E J ET AL, "new substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central a2-antagonistic activity as potential antidepressants", Biorg Med Chem Lett, 2000, vol. 10,pages 71 - 74 *

Also Published As

Publication number Publication date
CA2982217A1 (en) 2016-10-20
RU2717665C2 (ru) 2020-03-24
JP6847851B2 (ja) 2021-03-24
EP3283487A1 (en) 2018-02-21
CL2017002498A1 (es) 2018-04-20
RU2017139254A3 (enExample) 2019-09-30
US10280165B2 (en) 2019-05-07
JP2021046428A (ja) 2021-03-25
SG11201708294YA (en) 2017-11-29
CR20170462A (es) 2018-02-01
US20180127414A1 (en) 2018-05-10
UA120647C2 (uk) 2020-01-10
IL254921A0 (en) 2017-12-31
PH12017501876A1 (en) 2018-02-26
CN107531696B (zh) 2021-03-16
PE20180316A1 (es) 2018-02-09
EP3283487B1 (en) 2019-10-16
MX373162B (es) 2020-04-21
AU2016248886A1 (en) 2017-10-12
CO2017009989A2 (es) 2018-01-05
BR112017021083A2 (pt) 2018-07-03
MX2017013101A (es) 2018-01-30
HK1245259A1 (zh) 2018-08-24
CN107531696A (zh) 2018-01-02
RU2017139254A (ru) 2019-05-15
KR20170137137A (ko) 2017-12-12
JP2018511627A (ja) 2018-04-26
WO2016166078A1 (en) 2016-10-20
IL254921B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
EP3283487B1 (en) Pyridopyrimidinones and their use as nmda receptor modulators
CA3045032A1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
US10647731B2 (en) Thiazolopyrimidinones and methods of use thereof
RU2737737C2 (ru) АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI
MX2015001715A (es) Compuestos de pirrolopirimidina novedosos como inhibidores de proteinas quinasas.
RU2677698C1 (ru) Производные триазолопиридазина в качестве модуляторов активности tnf
TWI749126B (zh) Cdk4/6抑制劑
CA3209082A1 (en) Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders
JP7812861B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン
TW202043232A (zh) Pde9抑制劑及其用途
JP7041141B2 (ja) 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
KR101820541B1 (ko) 8-옥소디히드로퓨린 유도체
EP3738961A1 (en) Heterocyclic compound as csf-1r inhibitor and use thereof
WO2024017227A1 (zh) 取代的稠环大麻素受体化合物及其应用
CN116969888A (zh) 含环丙基并环类衍生物、其药学上可接受的盐及其制备方法和应用
JP2022534316A (ja) Ｃｄｃ７阻害剤としての四環式化合物
US20240132464A1 (en) Heterocyclic compounds as e3 ligase inhibitors
CA3046864C (en) Cdk4/6 inhibitor
HK1245259B (en) Pyridopyrimidinones and their use as nmda receptor modulators
HK40008902B (en) Cdk4/6 inhibitor
HK40052926A (en) Kras mutant protein inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired